“…(2020) . Program evaluations conducted in Europe, North America, Asia, and Africa suggested that most health care and harm reduction services for PWID, including HIV testing ( Frost et al., 2021 ; Htun Nyunt et al., 2021 ; Kra et al., 2021 ), HIV treatment ( Mistler et al., 2021 ), access to sterile injection equipment ( Croxford et al., 2021 ; Van Hout et al., 2021 ), and post-overdose care in emergency departments ( Collins et al., 2021 ), were negatively affected by the pandemic, though some programs were able to adapt quickly and innovate new forms of service delivery ( Van Hout et al., 2021 ; Wenger et al., 2021 ). Qualitative research exploring how the COVID-19 pandemic has shaped the lived experience of PWID remains limited to studies of overdose risks and the necessity of harm reduction services during pandemic conditions in parts of the United States and Canada ( Perri et al., 2021 ; Russell et al., 2021 ; Stack et al., 2021 ).…”